Clinical immunology: The new immunotherapies
This year’s HOT TOPIC focuses on “Clinical immunology: The new immunotherapies“, for the practising dermatologist. 32 of Europe’s leading immunologists will teach us clinicians what we need to know about allergic, autoimmune and auto-inflammatory diseases, immune-deficiencies, as well as the immunotherapies of infectious and malignant diseases.
Below is a preview of the stimulating topics that will be discovered and covered over the two full days…
Day 1 – Thursday, 14 September
Clinical immunology: Allergic diseases
- Pathogenesis of sensitisation
- Type I and type IV allergies
- Environmental factors and allergy
- IgE mediated diseases, mast cell dysfunction and their treatment
- Contact hypersensitivity
- Atopic dermatitis
- IL-4/IL-13 antagonists: How do they work?
Clinical immunology: Autoimmune diseases
- Antibody-mediated autoimmune diseases: Using pemphigus as a model
- Cell-mediated autoimmune diseases: Using lichen planus as a model
- Bullous autoimmune diseases: Why do they look different?
- TNF and TNF antagonist: How do they work?
- IL-12 antagonists and T-cell based immunosuppression
- IL-17/IL-23 and their antagonists: How do they work?
- B-cell based immunosuppression
- Intravenous immunoglobulins
Day 2 – Friday, 15 September
Clinical immunology: Auto-inflammatory diseases
- Definition and spectrum of auto-inflammatory diseases
- Inflammasome: An intracellular sensor of danger
- IL-1, IL-1 antagonists and fever syndromes
- IL-1 family and pustular diseases
Clinical immunology: Immunodeficiencies
- Primary immune-deficiencies relevant to dermatology
- Immunodeficiencies in HIV infection
- Risks of small molecule-immuno-suppressants
- Infections induced by natalizumab, CTLA-4-Ig, B-cell depletion and related drugs
Clinical immunology: Immunotherapy of infectious diseases
- Beta-defensins in cutaneous infection
- Modes of adaptive immunity to infection
- HPV and zoster vaccines: Mode of action and efficacy
- Live attenuated and inactivated vaccines: Benefits and risks
Clinical immunology: Immunotherapy of malignant diseases
- Tumour microenvironment
- New perspectives for anti-cancer vaccines: Personalisation and combination
- Exploiting antiviral defense for cancer immunotherapy
- CTLA4 and PD-1/PD-L1 antagonists: Mode of action
The full programme with confirmed speakers is available for viewing here.